|
TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.
|
|
Please join us this November at the premier rheumatology scientific meeting. This year's meeting will be held at the
Philadelphia Convention Center (1101 Arch St, Philadelphia, PA 19107) from Thursday, November 10, 2022, through Monday,
November 14, 2022. Visit the TREMFYA® booth (#2201)
and unite with your peers in signing a declaration in support of your patients.
|
|
|
|
IMPORTANT SAFETY INFORMATION
|
CONTRAINDICATIONS
TREMFYA® is contraindicated in patients with a history
of serious hypersensitivity reaction to guselkumab or
to any of the excipients.
|
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including
anaphylaxis, have been reported with postmarket use
of TREMFYA®. Some cases required hospitalization. If a
serious hypersensitivity reaction occurs, discontinue
TREMFYA® and initiate appropriate therapy.
|
Infections
TREMFYA® may increase the risk of infection.
Treatment with TREMFYA® should not be initiated in
patients with a clinically important active infection
until the infection resolves or is adequately treated.
Consider the risks and benefits of treatment prior to
prescribing TREMFYA® in patients with a chronic
infection or a history of recurrent infection. Instruct
patients receiving TREMFYA® to seek medical help if
signs or symptoms of clinically important chronic or
acute infection occur. If a patient develops a clinically
important or serious infection, or is not responding to
standard therapy, closely monitor and discontinue
TREMFYA® until the infection resolves.
|
Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating
treatment with TREMFYA®. Initiate treatment of latent
TB prior to administering TREMFYA®. Monitor patients
for signs and symptoms of active TB during and after
TREMFYA® treatment. Do not administer TREMFYA® to
patients with active TB infection.
|
Immunizations
Prior to initiating TREMFYA®, consider completion of all
age-appropriate immunizations according to current
immunization guidelines. Avoid use of live vaccines in
patients treated with TREMFYA®.
|
ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated
with TREMFYA® include upper respiratory infections,
headache, injection site reactions, arthralgia,
bronchitis, diarrhea, gastroenteritis, tinea infections,
and herpes simplex infections.
The overall safety profile observed in patients with
psoriatic arthritis is generally consistent with the
safety profile in patients with plaque psoriasis, with
the addition of bronchitis and neutrophil count
decreased.
|
Please read the full Prescribing Information and
Medication Guide for TREMFYA®. Provide the
Medication Guide to your patients and encourage
discussion.
|
cp-82625v3
|
|
If you no longer wish to receive e-mails from Janssen,
|
please click unsubscribe | Privacy Policy.
|
Developed under the direction and sponsorship of Janssen Biotech, Inc.
|
Janssen Biotech, Inc. | 800 Ridgeview Drive | Horsham, PA 19044
|
© Janssen Biotech, Inc. 2022 09/22 cp-341668v1
|
|